For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 11,498,761 | |||
| General and administrative | 11,481,083 | |||
| Total operating expenses | 22,979,844 | |||
| Loss from operations | -22,979,844 | |||
| Gain on valuation of warrants | -753,707 | |||
| Interest income | 435,100 | |||
| Total other income (expense), net | 1,188,807 | |||
| Loss before income taxes | -21,791,037 | |||
| Net loss | -21,791,037 | |||
| Basic EPS | -8.35 | |||
| Diluted EPS | -8.35 | |||
| Basic Average Shares | 2,608,317 | |||
| Diluted Average Shares | 2,608,317 | |||
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)